Koers Eisai Co., Ltd. OTC Markets
Aandelen
ESALY
US2825793092
Farmaceutische producten
Omzet 2025 * | 764 mld. 4,75 mld. 4,39 mld. | Omzet 2026 * | 842 mld. 5,24 mld. 4,83 mld. | Marktkapitalisatie | 1.859 mld. 11,57 mld. 10,68 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2025 * | 45,23 mld. 281 mln. 260 mln. | Nettowinst (verlies) 2026 * | 62,03 mld. 386 mln. 356 mln. | EV/omzet 2025 * | 2,18 x |
Nettoliquiditeiten 2025 * | 195 mld. 1,21 mld. 1,12 mld. | Nettoliquiditeiten 2026 * | 200 mld. 1,25 mld. 1,15 mld. | EV/omzet 2026 * | 1,97 x |
K/w-verhouding 2025 * |
41,1
x | K/w-verhouding 2026 * |
29,9
x | Werknemers | 11.067 |
Dividendrendement 2025 * |
2,48% | Dividendrendement 2026 * |
2,58% | Vrij verhandelbaar | 93,85% |
Recentste transcriptie over Eisai Co., Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01-10-75 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Keisuke Naito
COO | Chief Operating Officer | 35 | 01-10-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01-10-75 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 01-06-21 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+57,70% | 823 mld. | |
-6,86% | 353 mld. | |
+15,51% | 320 mld. | |
+7,64% | 295 mld. | |
+13,62% | 239 mld. | |
+14,55% | 220 mld. | |
-0,33% | 219 mld. | |
+8,20% | 167 mld. | |
-3,00% | 159 mld. |